The goal of this trial is to assess the impact of focal HIFU therapy on quality of life in patients with favourable intermediate-risk localised prostate cancer. The main question it aims to answer is:

What is the prostate cancer-related quality of life in patients with favourable intermediate-risk localised cancer treated by total prostatectomy or focal HIFU ?

Researchers will compare patients with favourable intermediate-risk localised cancer treated by total prostatectomy to patients with favourable intermediate-risk localised cancer treated by focal HIFU to see their quality of life.

Participants will answer EPIC-CP questionnaire 6 months, 12 months and 24 months after treatment

Inclusion Criteria:

• Patient, male, aged between ≥ 40 and ≤ 75 years
• Patient with a life expectancy > 10 years at the time of inclusion.
• Patient with a therapeutic strategy (prostatectomy or focal HIFU) defined during a PCR.
• Patient with a diagnosis of localised prostate cancer at favourable intermediate risk
• Patient able to tolerate general anaesthesia or type IV sedation
• Patient with normal urinary continence status
• Patient with satisfactory erectile function allowing penetration:
• Patient with targeted biopsies and systematic biopsies
• Patient affiliated to or benefiting from a social security scheme
• French-speaking patients who do not object to the use of their data.

Exclusion Criteria:

• Patients with a contraindication to MRI
• Stage T3a or b on MRI
• Patient on long-term anticoagulants and unable to stop them.
• Patient already included in another study
• Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision

This study deals with prostate cancer so that only men are eligible to participate